Brief: Nexalin Technology Announces UCSD IRB Approval For Use Of HALO Clarity In Clinical Trials For mTBI And PTSD Treatment
18/02/2025 14:58
Feb 18 (Reuters) - Nexalin Technology Inc NXL.O :
* NEXALIN TECHNOLOGY ANNOUNCES UCSD IRB APPROVAL FOR USE OF
HALO™
CLARITY IN CLINICAL TRIALS FOR MTBI AND PTSD TREATMENT
Source text: ID:nGNX3pt1ml
Further company coverage: NXL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalin Technology
See all newsBrief: Nexalin Technology Regains Compliance With Nasdaq Minimum Bid Price Requirement Nasdaq Hearings Panel Grants Request For Continued Listing
NASDAQ RESUMED AT 12:48 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:43 PM
NASDAQ RESUMED AT 10:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:24 AM